Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Twist Bioscience

DB:0ME
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0ME
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Twist Bioscience has significant price volatility in the past 3 months.
0ME Share Price and Events
7 Day Returns
10%
DB:0ME
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-1.7%
DB:0ME
-7.4%
DE Biotechs
-14.2%
DE Market
0ME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Twist Bioscience (0ME) 10% -19.9% 28.7% -1.7% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 0ME outperformed the Biotechs industry which returned -7.4% over the past year.
  • 0ME outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

0ME Value

 Is Twist Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Twist Bioscience. This is due to cash flow or dividend data being unavailable. The share price is €24.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Twist Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Twist Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0ME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.55
NasdaqGS:TWST Share Price ** NasdaqGS (2020-04-08) in USD $27.43
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Twist Bioscience.

DB:0ME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TWST Share Price ÷ EPS (both in USD)

= 27.43 ÷ -4.55

-6.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Twist Bioscience is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Twist Bioscience is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Twist Bioscience's expected growth come at a high price?
Raw Data
DB:0ME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
14.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Twist Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Twist Bioscience's assets?
Raw Data
DB:0ME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.10
NasdaqGS:TWST Share Price * NasdaqGS (2020-04-08) in USD $27.43
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:0ME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TWST Share Price ÷ Book Value per Share (both in USD)

= 27.43 ÷ 3.10

8.85x

* Primary Listing of Twist Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Twist Bioscience is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Twist Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Twist Bioscience has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0ME Future Performance

 How is Twist Bioscience expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Twist Bioscience expected to grow at an attractive rate?
  • Unable to compare Twist Bioscience's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Twist Bioscience's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Twist Bioscience's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0ME Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0ME Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 14.3%
DB:0ME Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 24.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0ME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0ME Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 206 -92 1
2023-09-30 172 -103 1
2022-09-30 153 -21 -58 4
2021-09-30 118 -33 -71 4
2020-09-30 79 -115 -135 4
2020-04-08
DB:0ME Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 60 -101 -141
2019-09-30 54 -88 -108
2019-06-30 47 -81 -96
2019-03-31 40 -76 -86
2018-12-31 33 -72 -77
2018-09-30 25 -66 -71
2018-06-30 20 -61 -68
2017-09-30 11 -51 -59

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Twist Bioscience is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Twist Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0ME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Twist Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0ME Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30 -2.16 -2.16 -2.16 1.00
2023-09-30 -2.50 -2.50 -2.50 1.00
2022-09-30 -1.45 0.08 -2.75 3.00
2021-09-30 -1.87 -0.26 -3.31 3.00
2020-09-30 -3.88 -3.71 -4.16 3.00
2020-04-08
DB:0ME Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.55
2019-09-30 -3.92
2019-06-30 -4.79
2019-03-31 -6.50
2018-12-31 -11.10
2018-09-30 -25.51
2018-06-30 -25.57
2017-09-30 -24.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Twist Bioscience will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Twist Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Twist Bioscience has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0ME Past Performance

  How has Twist Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Twist Bioscience's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Twist Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Twist Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Twist Bioscience's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Twist Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Twist Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0ME Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 60.06 -140.67 91.27 38.71
2019-09-30 54.39 -107.67 80.13 35.68
2019-06-30 47.06 -96.29 68.66 31.25
2019-03-31 40.00 -86.00 58.59 27.51
2018-12-31 32.61 -76.94 49.45 23.32
2018-09-30 25.43 -71.24 43.45 20.35
2018-06-30 20.49 -68.44 38.91 19.13
2017-09-30 10.77 -59.31 26.06 19.17
2016-09-30 2.27 -44.09 18.27 18.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Twist Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Twist Bioscience has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Twist Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Twist Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Twist Bioscience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0ME Health

 How is Twist Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Twist Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Twist Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Twist Bioscience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Twist Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 18.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Twist Bioscience Company Filings, last reported 3 months ago.

DB:0ME Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 103.08 7.00 103.11
2019-09-30 152.08 7.73 138.11
2019-06-30 176.00 8.45 161.79
2019-03-31 115.48 9.16 104.32
2018-12-31 138.60 9.86 130.17
2018-09-30 89.69 9.72 80.76
2018-06-30 96.46 9.54 92.50
2017-09-30 66.92 9.15 62.20
2016-09-30 57.81 11.18 55.92
  • Twist Bioscience's level of debt (6.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Twist Bioscience's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Twist Bioscience has less than a year of cash runway based on current free cash flow.
  • Twist Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.1% each year.
X
Financial health checks
We assess Twist Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Twist Bioscience has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0ME Dividends

 What is Twist Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Twist Bioscience dividends.
If you bought €2,000 of Twist Bioscience shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Twist Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Twist Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0ME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0ME Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Twist Bioscience has not reported any payouts.
  • Unable to verify if Twist Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Twist Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Twist Bioscience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Twist Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Twist Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Twist Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0ME Management

 What is the CEO of Twist Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Emily Leproust
COMPENSATION $8,126,157
AGE 46
TENURE AS CEO 7 years
CEO Bio

Dr. Emily Marine Leproust, Ph.D., co-founded Twist Bioscience Corporation and serves as its Chief Executive Officer. Dr. Leproust has been Director of Twist Bioscience Corporation since April 2013 and serves as its President. She architected the successful SureSelect product line which lowered the cost of sequencing and elucidated dozens of mendelian diseases and she developed Agilent’s Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team as well as co-led marketing and sales efforts associated with the product line. Dr. Leproust designed and executed multiple experimental synthesis platforms to streamline manufacturing and fabrication. Dr. Leproust has co-authored over 34 peer-reviewed papers, many on synthetic DNA and has extensive marketing, management and business development experience. Prior to Twist Bioscience, she was Director of Applications and Chemistry R&D—Genomics at Agilent Technologies, where she built and led the fastest growing product line, resulting in more than $100 million in revenues and more than 300 customer publications. Prior to Agilent, she worked with Dr. X. Gau at the University of Texas developing DNA and RNA parallel synthesis processes on solid support, a project developed commercially by Xeotron Corporation. She earned her Ph.D. in organic chemistry from the University of Houston and her M.Sc. in industrial chemistry from the Lyon School of Industrial Chemistry in France.

CEO Compensation
  • Emily's compensation has increased whilst company is loss making.
  • Emily's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Twist Bioscience management team in years:

1.8
Average Tenure
50.5
Average Age
  • The average tenure for the Twist Bioscience management team is less than 2 years, this suggests a new team.
Management Team

Emily Leproust

TITLE
Co-Founder
COMPENSATION
$8M
AGE
46
TENURE
7 yrs

Jim Thorburn

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
64
TENURE
2 yrs

Paddy Finn

TITLE
Chief Commercial Officer
COMPENSATION
$3M
AGE
47
TENURE
1.3 yrs

Patrick Weiss

TITLE
Chief Operating Officer
AGE
48
TENURE
0.3 yrs

Mark Daniels

TITLE
Senior VP
COMPENSATION
$704K
AGE
56
TENURE
3.6 yrs

Paula Green

TITLE
Vice President of Human Resources
AGE
52
TENURE
4.1 yrs

Bill Banyai

TITLE
Senior VP of Advanced Development
AGE
64
TENURE
0.3 yrs

Aaron Sato

TITLE
Chief Scientific Officer of BioPharma & VP of Protein Engineering
TENURE
1.8 yrs

Martin Kunz

TITLE
Senior Vice President of Operations
AGE
49
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Twist Bioscience board of directors in years:

2.6
Average Tenure
59
Average Age
  • The average tenure for the Twist Bioscience board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bill Banyai

TITLE
Senior VP of Advanced Development
AGE
64
TENURE
7.2 yrs

Keith Crandell

TITLE
Independent Director
COMPENSATION
$90K
AGE
59
TENURE
6.5 yrs

Emily Leproust

TITLE
Co-Founder
COMPENSATION
$8M
AGE
46
TENURE
7 yrs

Rob Chess

TITLE
Lead Independent Director
COMPENSATION
$90K
AGE
62
TENURE
1.5 yrs

Jan Johannessen

TITLE
Independent Director
COMPENSATION
$430K
AGE
63
TENURE
1.5 yrs

Fred Craves

TITLE
Independent Director
COMPENSATION
$90K
AGE
73
TENURE
5.9 yrs

Xiaoying Mai

TITLE
Independent Director
AGE
32
TENURE
1.8 yrs

Bob Ragusa

TITLE
Independent Director
COMPENSATION
$90K
AGE
59
TENURE
3.4 yrs

Nelson Chan

TITLE
Director
COMPENSATION
$218K
AGE
58
TENURE
0.9 yrs

Nicolas Barthelemy

TITLE
Non-Employee Director
AGE
53
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Sep 19 Sell Mark Daniels Individual 16. Sep 19 16. Sep 19 -1,500 €27.19 €-40,782
23. Aug 19 Sell Patrick Weiss Individual 22. Aug 19 22. Aug 19 -3,000 €27.47 €-78,940
X
Management checks
We assess Twist Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Twist Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0ME News

Simply Wall St News

0ME Company Info

Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has collaboration agreements with Pandion Therapeutics, Inc. and Schrödinger Inc. The company was founded in 2013 and is headquartered in South San Francisco, California.

Details
Name: Twist Bioscience Corporation
0ME
Exchange: DB
Founded: 2013
$1,028,800,982
40,785,576
Website: http://www.twistbioscience.com
Address: Twist Bioscience Corporation
681 Gateway Boulevard,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TWST Common Stock Nasdaq Global Select US USD 31. Oct 2018
DB 0ME Common Stock Deutsche Boerse AG DE EUR 31. Oct 2018
Number of employees
Current staff
Staff numbers
414
Twist Bioscience employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:48
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.